Get the Stockscreener App
5.40
4.09%
-0.23
Journey Medical Corp stock is traded at $5.40, with a volume of 20,630.
It is down -4.09% in the last 24 hours and up +11.57% over the past month.
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
See More
Previous Close:
$5.63
Open:
$5.66
24h Volume:
20,630
Relative Volume:
0.29
Market Cap:
$111.32M
Revenue:
$79.89M
Net Income/Loss:
$-12.35M
P/E Ratio:
-6.506
EPS:
-0.83
Net Cash Flow:
$32.92M
1W Performance:
+0.75%
1M Performance:
+11.57%
6M Performance:
+12.73%
1Y Performance:
+30.75%
1-Day Range:
$5.329
$5.74
1-Week Range:
$5.1751
$5.862
52-Week Range:
$2.85
$6.8899
Journey Medical Corp Stock (DERM) Company Profile
Name
Journey Medical Corp
Sector
Phone
480-434-6670
Address
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE
Compare DERM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DERM
Journey Medical Corp
|
5.40 | 111.32M | 79.89M | -12.35M | 32.92M | -0.83 |
|
ZTS
Zoetis Inc
|
168.78 | 75.15B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.58 | 47.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.94 | 47.70B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.16 | 18.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.30 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Journey Medical Corp Stock (DERM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | ROTH MKM | Buy |
| Dec-07-21 | Initiated | B. Riley Securities | Buy |
Journey Medical Corp Stock (DERM) Latest News
Rap star Pusha T's 'favorite business' venture is surprisingly a US medical-based service company. It started small but now operates in 7 cities. Here's what it does - Moneywise
Journey Medical CFO Joseph Benesch sells $7,084 in stock By Investing.com - Investing.com Australia
Journey Medical CFO Joseph Benesch sells $7,084 in stock - Investing.com India
Paul Lewis Cicalo Sr.2025Boylan-Journey Demo - Tribute Archive
Journey Medical Co. (NASDAQ:DERM) Short Interest Up 6.5% in January - MarketBeat
Meet Jahkil Jackson - Bold Journey Magazine
Tedy Bruschi: A Champion on a Heart Health Journey - Abbott
Pioneers of today embark on journey to yesteryear - St. Paul Pioneer Press
Outset medical stock news: OM stock poised for growth amid transformation - Markets.com
Strong Growth Potential and Strategic Market Positioning Drive Buy Rating for Journey Medical Corp. - TipRanks
Journey Medical Co. (NASDAQ:DERM) Short Interest Up 14.8% in January - MarketBeat
Journey Medical Corporation's (NASDAQ:DERM) biggest owners are public companies who got richer after stock soared 32% last week - Yahoo Finance
He ruled the operating room and then daytime TV. Now, Dr. Oz is set to take over a $1.5 trillion health agency - STAT
Navigating NLSP Stock: NLS Pharmaceutics Ltd Journey - The InvestChronicle
Short Interest in Journey Medical Co. (NASDAQ:DERM) Grows By 14.8% - Defense World
Journey Medical: FDA Approval For Emrosi Makes This An Exciting Stock (DERM) - Seeking Alpha
Tempus AI, Inc. (TEM): A Bull Case Theory - Yahoo Finance
National Public Health Week 2023 - U.S. Immigration and Customs Enforcement Newsroom
Minot Light Capital’s Largest Performance Detractor in Q4: Journey Medical (DERM) - Yahoo Finance
Sara Saito’s journey from tennis courts in Gunma to promising WTA pro - The Japan Times
Stocks on brokerages’ radar for January 24 - MSN
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea - Yahoo Finance
Journey Medical Sets Launch Date for Emrosi, New FDA-Approved Rosacea Treatment - StockTitan
SWK Holdings Provides Portfolio Update - ACCESS Newswire
Journey Medical Co. (NASDAQ:DERM) Sees Significant Increase in Short Interest - MarketBeat
Journey Medical Corp (NASDAQ: DERM): Sinking Weak -28.38% In 2025, Outlook Strong - Stocks Register
Intraoperative Imaging Market: The Journey From $2.76 Billion - openPR
60 Degrees Pharmaceuticals Inc (NASDAQ: SXTP) Jumps 0.32 Percent In Recent Trading, What Questions Do You Have? – Stocks Register - Stocks Register
IN8bio Inc (NASDAQ: INAB): What’s Next After The Stock Plunge? - Stocks Register
CIMG Inc (NASDAQ: IMG) Stock: Bulls Should Watch This - Stocks Register
This Data Shows Just How Strong Milestone Pharmaceuticals Inc (NASDAQ: MIST) Stock Is - Stocks Register
No Stopping Allarity Therapeutics Inc (NASDAQ: ALLR)’s Stock Surged? - Stocks Register
What Do Analysts Think Will Happen To Springview Holdings Ltd (NASDAQ: SPHL) - Stocks Register
PDS Biotechnology Corporation (NASDAQ: PDSB): Hidden Gems In A Time Of Volatility - Stocks Register
My journey to becoming a veterinary professional - DVM 360
Gryphon Bio, Inc. Pioneers Novel Blood Biomarker Panel to Monitor Treatment Journey for Patients with Traumatic Brain Injury and Alzheimer's - Yahoo Finance
Journey Medical Co. (NASDAQ:DERM) Shares Acquired by Geode Capital Management LLC - Defense World
DFD-29: The Journey to FDA Approval and a New Era in Rosacea Management - Dermatology Times
LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register
Tillys Inc (TLYS): Major Improvements, Worth A Look - Stocks Register
Apotex acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil) - BioSpace
Journey Medical (NASDAQ:DERM) Shares Down 5.3%Here's Why - MarketBeat
Malaysia’s education, business, healthcare AI journey in 2024 - The Malaysian Reserve
Step into ukiyo-e: A digital journey through Japan’s traditional art form - The Japan Times
Jim Cramer Says CVS Health Corporation (CVS) Is Going To Be ‘Challenged In Every Part Of The Business’ - Yahoo Finance
Bridgebio’s Attruby FDA nod boosts stock; 10 November approvals - BioWorld Online
One Man Shares His Journey With ATTR-CM - Health Central
Journey Medical Decline Means Insider Profits Down To US$101k - Simply Wall St
Journey Medical Corp Stock (DERM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):